Header Logo

Connection

RACHELLE DOODY to Disease Progression

Back to Details
This is a "connection" page, showing publications RACHELLE DOODY has written about Disease Progression.
RACHELLE DOODY
Connection Strength
1.683
Disease Progression
  1. Different Cognitive Profiles Are Associated with Progression Rate and Age at Death in Probable Alzheimer's Disease. J Alzheimers Dis. 2021; 80(2):735-747.
    View in: PubMed
    Score: 0.479
  2. Sustained effect of prasinezumab on Parkinson's disease motor progression in the open-label extension of the PASADENA trial. Nat Med. 2024 Dec; 30(12):3669-3675.
    View in: PubMed
    Score: 0.155
  3. Longitudinal Sensitivity of Alzheimer's Disease Severity Staging. Am J Alzheimers Dis Other Demen. 2020 Jan-Dec; 35:1533317520918719.
    View in: PubMed
    Score: 0.112
  4. Cognitively-Related Basic Activities of Daily Living Impairment Greatly Increases the Risk of Death in Alzheimers Disease. PLoS One. 2016; 11(8):e0160671.
    View in: PubMed
    Score: 0.089
  5. Predicting disease progression in progressive supranuclear palsy in multicenter clinical trials. Parkinsonism Relat Disord. 2016 07; 28:41-48.
    View in: PubMed
    Score: 0.086
  6. Binomial regression with a misclassified covariate and outcome. Stat Methods Med Res. 2016 Feb; 25(1):101-17.
    View in: PubMed
    Score: 0.065
  7. Dementia staging across three different methods. Dement Geriatr Cogn Disord. 2011; 31(5):328-33.
    View in: PubMed
    Score: 0.061
  8. Plasma sphingomyelins are associated with cognitive progression in Alzheimer's disease. J Alzheimers Dis. 2011; 27(2):259-69.
    View in: PubMed
    Score: 0.060
  9. Evolving early (pre-dementia) Alzheimer's disease trials: suit the outcomes to the population and study design. J Nutr Health Aging. 2010 Apr; 14(4):299-302.
    View in: PubMed
    Score: 0.057
  10. Donepezil treatment of patients with MCI: a 48-week randomized, placebo-controlled trial. Neurology. 2009 May 05; 72(18):1555-61.
    View in: PubMed
    Score: 0.052
  11. Importance of subtle amnestic and nonamnestic deficits in mild cognitive impairment: prognosis and conversion to dementia. Dement Geriatr Cogn Disord. 2007; 24(6):476-82.
    View in: PubMed
    Score: 0.048
  12. Baseline cognitive function predicts rate of decline in basic-care abilities of individuals with dementia of the Alzheimer's type. Arch Clin Neuropsychol. 2007 Jan; 22(1):99-107.
    View in: PubMed
    Score: 0.045
  13. Individual growth curve analysis of APOE epsilon 4-associated cognitive decline in Alzheimer disease. Arch Neurol. 2005 Mar; 62(3):454-9.
    View in: PubMed
    Score: 0.040
  14. Prasinezumab slows motor progression in rapidly progressing early-stage Parkinson's disease. Nat Med. 2024 Apr; 30(4):1096-1103.
    View in: PubMed
    Score: 0.038
  15. A method for estimating duration of illness in Alzheimer's disease. Dement Geriatr Cogn Disord. 2004; 17(1-2):1-4.
    View in: PubMed
    Score: 0.036
  16. A trial of gantenerumab or solanezumab in dominantly inherited Alzheimer's disease. Nat Med. 2021 Jul; 27(7):1187-1196.
    View in: PubMed
    Score: 0.031
  17. A method for estimating progression rates in Alzheimer disease. Arch Neurol. 2001 Mar; 58(3):449-54.
    View in: PubMed
    Score: 0.030
  18. The influence of handedness on the clinical presentation and neuropsychology of Alzheimer disease. Arch Neurol. 1999 Sep; 56(9):1133-7.
    View in: PubMed
    Score: 0.027
  19. Statistical Model of Dynamic Markers of the Alzheimer's Pathological Cascade. J Gerontol B Psychol Sci Soc Sci. 2018 08 14; 73(6):964-973.
    View in: PubMed
    Score: 0.025
  20. Prediction of Conversion to Alzheimer's Disease with Longitudinal Measures and Time-To-Event Data. J Alzheimers Dis. 2017; 58(2):361-371.
    View in: PubMed
    Score: 0.023
  21. Designing drug trials for Alzheimer's disease: what we have learned from the release of the phase III antibody trials: a report from the EU/US/CTAD Task Force. Alzheimers Dement. 2013 Jul; 9(4):438-44.
    View in: PubMed
    Score: 0.018
  22. Report of the task force on designing clinical trials in early (predementia) AD. Neurology. 2011 Jan 18; 76(3):280-6.
    View in: PubMed
    Score: 0.015
  23. Characteristics and performance of a modified version of the ADCS-CGIC CIBIC+ for mild cognitive impairment clinical trials. Alzheimer Dis Assoc Disord. 2009 Jul-Sep; 23(3):260-7.
    View in: PubMed
    Score: 0.013
  24. Korean version of the Baylor Profound Mental Status Examination: a brief staging measure for patients with severe Alzheimer's disease. Dement Geriatr Cogn Disord. 2009; 27(1):69-75.
    View in: PubMed
    Score: 0.013
  25. Donepezil preserves cognition and global function in patients with severe Alzheimer disease. Neurology. 2007 Jul 31; 69(5):459-69.
    View in: PubMed
    Score: 0.012
  26. Influence of premorbid IQ and education on progression of Alzheimer's disease. Dement Geriatr Cogn Disord. 2006; 22(4):367-77.
    View in: PubMed
    Score: 0.011
  27. Realistic expectations for treatment success in Alzheimer's disease. J Nutr Health Aging. 2006 Sep-Oct; 10(5):417-29.
    View in: PubMed
    Score: 0.011
  28. A 24-week open-label extension study of memantine in moderate to severe Alzheimer disease. Arch Neurol. 2006 Jan; 63(1):49-54.
    View in: PubMed
    Score: 0.011
  29. Vitamin E and donepezil for the treatment of mild cognitive impairment. N Engl J Med. 2005 Jun 09; 352(23):2379-88.
    View in: PubMed
    Score: 0.010
  30. Memantine in moderate-to-severe Alzheimer's disease. N Engl J Med. 2003 Apr 03; 348(14):1333-41.
    View in: PubMed
    Score: 0.009
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.